| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |